

NC Fall 2010 HIV/STD Update September 23, 2010

### *Trichomoniasis:* Testing and Treatment Update

Arlene C. Sena, MD, MPH Medical Director, Durham County Health Department Associate Professor, University of North Carolina Infectious Diseases

Acknowledgements: Marcia Hobbs, PhD

# Outline

- Epidemiology of T. vaginalis infections
- Clinical presentations of trichomoniasis
- *T. vaginalis* detection and improved diagnostic methods
- Treatment considerations
- HIV interactions

# What's in a name?

From the Greek:

- trichos, hair
- monas, unit, single

Trichomonads in vaginal discharge first described by Alfred Donné in 1863



edical Parasitology, 3rd. edition. Edward K arkell & Henrietta Voge. Imstrip II, Frame 34







### Associations with Trichomoniasis

- HIV
- Risk of other STDs (gonorrhea, HSV)
- Cervical neoplasia (HPV)
- Tubal infertility
- Post-hysterectomy infection
- Atypical PID
- Preterm birth





# Clinical presentation in women

- Common sites of *T. vaginalis* infection in include the vagina, urethra, and endocervix
- Symptoms include vaginal discharge, itching, odor, dysuria (though commonly asymptomatic)
- Elevated vaginal pH, amines
- Frothy discharge and strawberry cervix are classic findings on exam



# Clinical presentation in men

- Non-gonococcal, nonchlamydial urethritis
- Symptoms include urethral discharge, dysuria (though commonly asymptomatic)
- T. vaginalis can be isolated from men with chronic prostatitis



#### T. Vaginalis Diagnostics

- Wet mount microscopy
- Culture
- Rapid antigen detection
- Nucleic acid amplification tests (NAATs)
  - in-house polymerase chain reaction (PCR)
  - commercially available transcription mediated assays (TMA)

#### Wet mount microscopy

- Performed on vaginal swab specimens (or male urine sediment) resuspended in a drop or 2 of saline
- Organisms must be viable and motile
- Must be performed within 15
  minutes of specimen
  collection
- 50 70% sensitivity with expert microscopist



#### T. vaginalis culture

- Trich grows best in microaerophilic or anaerobic environments
- CO<sub>2</sub> incubator or anaerobe jars, 35 -37 °C, pH 5 - 7.5
- Diamond's medium with antifungal and antibacterial additives
- InPouch™ TV (Biomed)
- Cultures examined daily for up to 5 days
- Sensitivity estimates: 70 - 90% in women
   50 - 70% in men



# InPouch TV cultures from men require long incubation periods



## Rapid antigen detection



#### Recent advances in *T. vaginalis* detection (NAATs)

- Numerous in-house PCR assays in the literature
  - gel detection
  - ELISA detection
  - real-time PCR
- Gen-Probe, Inc. now has a commercial (not FDA cleared)Analyte Specific Reagent test using transcriptionmediated amplification (TMA)
- NAATs are more sensitive than other tests for *T. vaginalis* (~90 - 100%)
- Non-invasive specimens
  - urine
  - self-collected vaginal swabs

# TV detection in conjunction with CT and NG in women



CT and NG infect cervical epithelium TV infects the vagina

CT, NG and TV are 'bystanders' in urine. TV can be detected in vaginal and cervical swabs.

# *T. vaginalis* detection in men: where are the parasites?

- *T. vaginalis* is seldom included in studies of STDs in men.
- When it *is* sought, a urethral swab OR urine is usually collected for culture.
- The organism can be recovered from urethral swabs, urine, semen and rarely from the external genitalia.





#### T. vaginalis detection by PCR in men attending US STD clinics



### **Treatment of Trichomoniasis**

- Metronidazole 2 gm orally once
- Metronidazole 500 mg orally twice daily x 7 days

- Tinidazole
- Tinidazole 2 gm orally once also recommended regimen
- Clinical trials found cure rates between 86-100% in women, 83% in men.
- Compared to metronidazole, tinidazole has:
  - Higher clinical and microbiological cure rates
  - Less frequent side effects
  - Substantially higher cost (2gm @\$11 compared to \$.15)



• Metrogel NOT recommended; < 50% efficacious than oral</p> regimens



#### Treatment during Pregnancy and Lactation

#### • Pregnancy

- Metronidazole 2gm orally once
- Tinidazole safety NOT well evaluated (category C)
- Breast-feeding
  - Metronidazole withhold breastfeeding during treatment and for 12-24 hours after last dose
  - Tinidazole withhold breastfeeding during treatment and for 3 days after last dose

### Treatment in HIV-infected Persons

- CDC Treatment Guidelines 2006 recommend:
   Same treatment as those who are HIV negative
- Randomized phase IV trial of metronidazole single dose vs. 7 day dose for treatment of trichomoniasis among HIV-infected women
  - Involved 3 US sites
  - Conducted test-of-cure visit at 6-12 days posttreatment

#### Metronidazole Allergy

- Helms, 2008 reported hypersensitivity in 59 women: 47% with urticaria; 11% with facial edema
- 15 women had metronidazole desensitization and all were cured.
- 27 women had alternative intravaginal treatments (i.e. betadine douche, paromomycin, clotrimazole) and only 29.4% had cure
- Tinidazole also a nitroimidazole, not recommended

#### Metronidazole-Resistant *T. vaginalis*

- Clinical failures reported since 1962
- Treatment failures give 7 day regimen, then metronidazole 2 gm orally each day for 3-5 days
- Tinidazole has proven effective in a limited number of treatment failures from metronidazole
- Can consider tinidazole 2gm orally each day for 5 days
- If no improvement or persistent positive tests with no possibility of reinfection, contact CDC for susceptibility testing

#### Trich and HIV Interactions

- · In four African cities, cross sectional study – Low HIV (4-8%) = Low TV (3-17%) - High HIV (31-35%) = High TV (29-34%) Buve et al., 2001 AIDS 15:s89-s96
- Pregnant Congolese: – HIV-: TV 10% - HIV+: TV 18.6% (OR 2.0, 95% CI 1.1-3.6) Sutton *et al.*, 1999 Am J Obstet Gynecol 181:656-662
- HSV-2+ women in Zimbabwe HSV-2 only: TV 11%
   HSV-2 + HIV: TV 27% (X<sup>2</sup> P = 0.022)
   Cowan *et al.*, 2006 AIDS 20:261-267

# TV and HIV Acquisition

- Among 1335 HIV seronegative women in Kenya
   TV incidence was 23.6/100 py
   1.52-fold increased risk of HIV infection (95% CI: 1.04 2.24)
   McCleared ar 2.007 Jim6c 195868
- Among 4450 HIV seronegative women in Uganda and Zimbabwe TV prevalence among women who seroconverted was 11.3% vs 4.5% in controls
  - OR for HIV acquisition = 2.74 (95% CI 1.25 6.0)
- Among 4968 HIV seronegative women in South Africa and Zimbabwe

  - TV incidence was 6.5/100 py
     HR for HIV acquisition = 2.05 (95% CI 1.05 4.02)
     HR for TV acquisition among HIV+ women = 2.12 (95% CI 1.35 3.32)
     Maretzerge *et al.* 2010 Sex Trame Bio 37460

# TV and HIV Transmission

 Treatment of trichomoniasis reduces HIV RNA in vaginal fluid Wang *et al.* 2001 JID 183:1017-1022



# The canary in the coal mine?





Among 1578 HIV+ women on HAART Magnus et al. 2003

- Retrospective cohort study in HIV outpatient program in New Orleans 1990 - 2000
- TV detected by wet-mount microscopy
- Urine-based nucleic acid detection for CT/NG
- Genital warts diagnosed clinically

## *T. vaginalis* "no longer a minor STD"

- Trichomoniasis is highly prevalent, including among HIV+ women
- Testing guidelines not well-defined
   who should be screened?
  - what tests should be used?
- Better diagnostics available, but cheaper tests are needed
- Options limited for metronidazole allergic or resistant infections
- T. vaginalis may contribute to HIV acquisition and transmission